RecruitingPhase 2NCT06560905

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Sponsor

Royal Marsden NHS Foundation Trust

Enrollment

16 participants

Start Date

Mar 11, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Melanoma

Summary

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether a specialized scan called a PSMA PET-CT (commonly used in prostate cancer) can also detect and map melanoma that has spread to lymph nodes, potentially helping surgeons plan better operations. **You may be eligible if...** - You are a male aged 18 or older - You have biopsy-confirmed melanoma that has spread to lymph nodes (metastatic) - You are already scheduled for surgery as part of your standard care - You have had a standard FDG PET-CT scan as part of routine care **You may NOT be eligible if...** - You are female - You have or have had prostate cancer - You are taking hormone therapy targeting the androgen pathway - You have had Lu-177 PSMA therapy or barium studies within the past 10 days - You are not fluent in English Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.